We no longer support this browser. Using a supported browser will provide a better experience.

Please update your browser.

Close browser message

Treasury and Payments

Improve your working capital, reduce fraud and minimize the impact of unexpected disruptions with our treasury solutions—from digital portals to integrated payables and receivables—all designed to make your operations smoother and more efficient.

Learn more about our treasury solutions:

Commercial Real Estate

Get the strategic support to be successful throughout market and real estate cycles with insights, hands-on service, comprehensive financial solutions and unrivaled certainty of execution.

Learn more about our commercial real estate solutions:

International Banking

Global opportunities mean global challenges. But real success means understanding the local markets you serve—which is why we bring the business solutions, insights and market perspective you need. 

Learn more about our international banking solutions:


Biopharma, medtech faced tight funding in Q1

Our Biopharma and Medtech Deals and Funding reports explore the upfront cash, mergers, acquisitions and other trends seen since the new year.

When it comes to the life sciences industry, biopharma and medtech continue to power through market challenges.

Biopharma R&D partnerships ticked up slightly in the first three months of 2023, while venture continued its yearlong decline. In medtech, R&D partnerships and venture held steady in Q1, down from record highs during the pandemic.

J.P. Morgan’s biopharma therapeutics and medtech licensing reports examine activity in each sector to provide insights on industry trends we might see for the remainder of 2023. The reports, powered by DealForma, highlight:

  • Deal values in biopharma licensing partnerships
  • Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
  • Venture investment amounts in therapeutic and platform companies
  • The advanced therapies that are seeing healthy investment and dealmaking
  • IPO and M&A activity in each sector

Download the full reports to understand these life sciences dealmaking trends and see what they may mean for the months ahead.

Technology and Disruptive Commerce Healthcare Life Sciences Technology Startups Liquidity Management Credit and Financing Private Equity

Get in Touch and Stay Informed